EMCDDA Document Library

Displaying 1 - 10 of 22

no image available

Guidance for handling acute opioid withdrawals for doctors at hospitals and treatment centers

Identification of bottlenecks in the harm reduction facilities. Where possible: suggestions for improvements and examples of creative solution

no image available

Dutch national update on harm reduction and coronavirus (3 april 2020)

This document provides an update on harm reduction activities during the pandemic in the Nethderlands.

no image available

Social reintegration situation in reporting countries, compiled from 2012 national reports

This document provides a compilation of social-reintegration-related material information submitted to the EMCDDA by the members of the Reitox national focal points.

Publications thumbnail

An analysis of the costs of dismantling and cleaning up synthetic drug production sites in Belgium and the Netherlands

The production of synthetic drugs, measured by the number of manufacturing sites identified and the amount of drugs seized, shows an increasing trend. In the Netherlands, Schoenmakers and Mehlbaum (2017) recorded a rise in the number of sites used for the dumping of toxic waste from synthetic drugs...

publication cover

European Web Survey on Drugs (2016): patterns of use — emerging findings

This flyer present some preliminary findings from the European Web Survey on Drugs, based on the survey round carried out in 2016. The European Web Survey on Drugs project aims to develop and test a web survey tool, or tools, in order to collect information on the amounts of drugs used by...

no image available

Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands

no image available

HCV policies landscape in Europe, 2018 – EMCDDA commissioned study (contract CT.16.IBS.0156.1.0)

In the context of its contribution to monitoring HCV elimination among PWID in Europe, the EMCDDA conducted a study on current HCV policies, assessing if and how these refer to people who inject drugs (PWID). This document contains a compilation of information about the current HCV policies in all...

no image available

Purity, adulteration and price of drugs bought on‐line versus off‐line in the Netherlands

This scientific article was one of the 2018 EMCDDA scientific award winners, which celebrates scientific writing and distinguishes high-quality research in the field of illicit drugs. This article won the award in the category 'Markets and drug cultures' and the award was granted to first...

no image available

Screening and beyond. National hepatitis plan: a strategy for action, Netherlands

The national hepatitis plan “screening and beyond” officially launched in November 2016 was developed by a multidisciplinary commission representing all relevant stakeholders involved in research, treatment, prevention and control of hepatitis B and C. The plan focuses on five themes: 1) awareness...

Paper

HCV promotional material example: Hepatitis B and C testing: Why? Who? How?

A guidance paper on testing in community and harm reduction settings. The paper includes the key facts about hepatitis B and C; Harm reduction as prevention; key recommendations about awareness raising and testing and diagnosis. The main topic covered in the paper is about different screening...

.